Join
Live feed
·
NEWSReleasevia Quantisnow
Oncternal Therapeutics Inc. logo

Oncternal Therapeutics Completes Enrollment And Begins Dosing For Sixth Dose Cohort In Phase 1/2 Study Of ONCT-534 For Metastatic Castration-Resistant Prostate Cancer

ByQuantisnow·Wall Street's wire, on your screen.
ONCT· Oncternal Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ONCT (Oncternal Therapeutics Inc.) and more on Quantisnow.